Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more
Oncternal Therapeutics Inc (ONCT) - Net Assets
Latest net assets as of September 2024: $9.15 Million USD
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has net assets worth $9.15 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.60 Million) and total liabilities ($6.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.15 Million |
| % of Total Assets | 58.64% |
| Annual Growth Rate | 35.36% |
| 5-Year Change | 109.98% |
| 10-Year Change | 68.56% |
| Growth Volatility | 26798.44 |
Oncternal Therapeutics Inc - Net Assets Trend (1999–2023)
This chart illustrates how Oncternal Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncternal Therapeutics Inc (1999–2023)
The table below shows the annual net assets of Oncternal Therapeutics Inc from 1999 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $30.05 Million | -50.71% |
| 2022-12-31 | $60.97 Million | -30.81% |
| 2021-12-31 | $88.12 Million | -21.98% |
| 2020-12-31 | $112.95 Million | +689.20% |
| 2019-12-31 | $14.31 Million | -45.19% |
| 2018-12-31 | $26.11 Million | -31.76% |
| 2017-12-31 | $38.26 Million | +92.35% |
| 2016-12-31 | $19.89 Million | +969.98% |
| 2015-12-31 | $1.86 Million | -89.57% |
| 2014-12-31 | $17.83 Million | +66.88% |
| 2013-12-31 | $10.68 Million | -77.60% |
| 2012-12-31 | $47.70 Million | -33.63% |
| 2011-12-31 | $71.87 Million | +38.95% |
| 2010-12-31 | $51.73 Million | +691.17% |
| 2009-12-31 | $-8.75 Million | -127.33% |
| 2008-12-31 | $32.02 Million | -59.43% |
| 2007-12-31 | $78.92 Million | -18.68% |
| 2006-12-31 | $97.05 Million | +31.90% |
| 2005-12-31 | $73.58 Million | +15.13% |
| 2004-12-31 | $63.91 Million | +142.54% |
| 2003-12-31 | $-150.23 Million | -171.63% |
| 2002-12-31 | $-55.31 Million | -62.31% |
| 2001-12-31 | $-34.08 Million | -35.41% |
| 2000-12-31 | $-25.16 Million | -119933.33% |
| 1999-12-31 | $21.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncternal Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19683000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.01% |
| Other Comprehensive Income | $3.00K | 0.01% |
| Other Components | $227.82 Million | 758.10% |
| Total Equity | $30.05 Million | 100.00% |
Oncternal Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Oncternal Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Indo American Seafoods Tbk
JK:ISEA
|
$1.43 Million |
|
Thai Polycons Public Company Limited
BK:TPOLY
|
$1.43 Million |
|
NUCOR - Dusseldorf Stock Exchang
DU:NUO
|
$1.43 Million |
|
Prism Resources Inc.
V:PRS-H
|
$1.43 Million |
|
Diablo Resources Ltd
AU:DBO
|
$1.42 Million |
|
Copper Search Ltd
AU:CUS
|
$1.42 Million |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
$1.42 Million |
|
Evergreen Lithium Ltd
AU:EG1
|
$1.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncternal Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -158,300,000 to 30,052,000, a change of 188,352,000.
- Net loss of 39,479,000 reduced equity.
- Share repurchases of 156,000 reduced equity.
- New share issuances of 3,238,000 increased equity.
- Other comprehensive income decreased equity by 6,000.
- Other factors increased equity by 224,755,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.48 Million | -131.37% |
| Share Repurchases | $156.00K | -0.52% |
| Share Issuances | $3.24 Million | +10.77% |
| Other Comprehensive Income | $-6.00K | -0.02% |
| Other Changes | $224.75 Million | +747.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Oncternal Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.77x to 0.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.19 | $0.53 | x |
| 2000-12-31 | $-227.74 | $0.53 | x |
| 2001-12-31 | $-307.86 | $0.53 | x |
| 2002-12-31 | $-500.53 | $0.53 | x |
| 2003-12-31 | $-1359.54 | $0.53 | x |
| 2004-12-31 | $185.92 | $0.53 | x |
| 2005-12-31 | $198.23 | $0.53 | x |
| 2006-12-31 | $218.09 | $0.53 | x |
| 2007-12-31 | $158.10 | $0.53 | x |
| 2008-12-31 | $61.74 | $0.53 | x |
| 2009-12-31 | $-16.82 | $0.53 | x |
| 2010-12-31 | $93.14 | $0.53 | x |
| 2011-12-31 | $87.71 | $0.53 | x |
| 2012-12-31 | $53.16 | $0.53 | x |
| 2013-12-31 | $11.86 | $0.53 | x |
| 2014-12-31 | $15.26 | $0.53 | x |
| 2015-12-31 | $0.88 | $0.53 | x |
| 2016-12-31 | $9.56 | $0.53 | x |
| 2017-12-31 | $15.36 | $0.53 | x |
| 2018-12-31 | $7.83 | $0.53 | x |
| 2019-12-31 | $27.71 | $0.53 | x |
| 2020-12-31 | $-81.55 | $0.53 | x |
| 2021-12-31 | $-46.28 | $0.53 | x |
| 2022-12-31 | $-60.20 | $0.53 | x |
| 2023-12-31 | $10.22 | $0.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncternal Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -131.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5029.17%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.22x
- Recent ROE (-131.37%) is above the historical average (-246.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -3571.43% | 0.00% | 0.00x | 79.90x | $-752.10K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.30 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.66 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.34 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $829.10K |
| 2004 | -34.97% | -1197.00% | 0.03x | 1.14x | $-28.74 Million |
| 2005 | -50.07% | -974.06% | 0.05x | 1.13x | $-44.20 Million |
| 2006 | -36.59% | -473.15% | 0.06x | 1.33x | $-45.21 Million |
| 2007 | -51.14% | -566.36% | 0.04x | 2.02x | $-48.25 Million |
| 2008 | -161.72% | -382.76% | 0.13x | 3.38x | $-54.98 Million |
| 2009 | 0.00% | -314.03% | 0.26x | 0.00x | $-45.38 Million |
| 2010 | 29.57% | 25.23% | 0.94x | 1.24x | $10.12 Million |
| 2011 | -46.32% | -225.89% | 0.19x | 1.09x | $-40.48 Million |
| 2012 | -56.76% | 0.00% | 0.00x | 1.21x | $-31.85 Million |
| 2013 | -394.15% | 0.00% | 0.00x | 1.46x | $-43.18 Million |
| 2014 | -221.05% | 0.00% | 0.00x | 2.84x | $-41.19 Million |
| 2015 | -1006.08% | 0.00% | 0.00x | 17.23x | $-18.89 Million |
| 2016 | -89.11% | 0.00% | -0.10x | 1.23x | $-19.71 Million |
| 2017 | -79.56% | -1818.34% | 0.04x | 1.21x | $-34.27 Million |
| 2018 | -147.13% | -1523.92% | 0.08x | 1.20x | $-41.03 Million |
| 2019 | -111.18% | -656.16% | 0.11x | 1.52x | $-17.34 Million |
| 2020 | 0.00% | -509.90% | 0.03x | 0.00x | $-8.93 Million |
| 2021 | 0.00% | -725.38% | 0.05x | 0.00x | $-19.89 Million |
| 2022 | 0.00% | -2912.28% | 0.02x | 0.00x | $-27.56 Million |
| 2023 | -131.37% | -5029.17% | 0.02x | 1.22x | $-42.48 Million |
Industry Comparison
This section compares Oncternal Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncternal Therapeutics Inc (ONCT) | $9.15 Million | -3571.43% | 0.71x | $1.43 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |